Alpha Teknova (TKNO) Competitors

$3.72 -0.19 (-4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$3.72 0.00 (0.00%)

As of 04:10 PM Eastern

TKNO vs. IVA, GYRE, BIOA, SLDB, and CTMX

Should you buy Alpha Teknova stock or one of its competitors? MarketBeat compares Alpha Teknova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alpha Teknova include Inventiva (IVA), Gyre Therapeutics (GYRE), BioAge Labs (BIOA), Solid Biosciences (SLDB), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

How does Alpha Teknova compare to Inventiva?

Inventiva (NASDAQ:IVA) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Inventiva has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Alpha Teknova has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	159.77	-$400.67M	N/A	N/A
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A

In the previous week, Alpha Teknova had 3 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Alpha Teknova and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat Alpha Teknova's score of 0.41 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 12.5% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inventiva has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Inventiva's return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Alpha Teknova	-41.07%	-24.32%	-16.34%

Inventiva currently has a consensus target price of $16.56, indicating a potential upside of 198.30%. Alpha Teknova has a consensus target price of $8.00, indicating a potential upside of 115.05%. Given Inventiva's stronger consensus rating and higher probable upside, equities research analysts clearly believe Inventiva is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Inventiva beats Alpha Teknova on 12 of the 15 factors compared between the two stocks.

How does Alpha Teknova compare to Gyre Therapeutics?

Alpha Teknova (NASDAQ:TKNO) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Gyre Therapeutics has a net margin of -5.44% compared to Alpha Teknova's net margin of -41.07%. Gyre Therapeutics' return on equity of 3.13% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Alpha Teknova has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market.

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gyre Therapeutics has higher revenue and earnings than Alpha Teknova. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A
Gyre Therapeutics	$117.05M	5.80	$5.03M	-$0.09	N/A

In the previous week, Gyre Therapeutics had 9 more articles in the media than Alpha Teknova. MarketBeat recorded 14 mentions for Gyre Therapeutics and 5 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.41 beat Gyre Therapeutics' score of -0.13 indicating that Alpha Teknova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Teknova currently has a consensus price target of $8.00, suggesting a potential upside of 115.05%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 142.86%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gyre Therapeutics beats Alpha Teknova on 12 of the 17 factors compared between the two stocks.

How does Alpha Teknova compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Alpha Teknova (NASDAQ:TKNO) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

BioAge Labs has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

13.8% of Alpha Teknova shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioAge Labs currently has a consensus price target of $45.00, suggesting a potential upside of 140.38%. Alpha Teknova has a consensus price target of $8.00, suggesting a potential upside of 115.05%. Given BioAge Labs' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioAge Labs is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Alpha Teknova has a net margin of -41.07% compared to BioAge Labs' net margin of -871.75%. Alpha Teknova's return on equity of -24.32% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Alpha Teknova has higher revenue and earnings than BioAge Labs. Alpha Teknova is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	80.67	-$80.61M	-$2.40	N/A
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A

In the previous week, BioAge Labs had 5 more articles in the media than Alpha Teknova. MarketBeat recorded 10 mentions for BioAge Labs and 5 mentions for Alpha Teknova. BioAge Labs' average media sentiment score of 0.73 beat Alpha Teknova's score of 0.41 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioAge Labs beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.

How does Alpha Teknova compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 1.9% of Solid Biosciences shares are held by insiders. Comparatively, 12.5% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Solid Biosciences had 3 more articles in the media than Alpha Teknova. MarketBeat recorded 8 mentions for Solid Biosciences and 5 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.41 beat Solid Biosciences' score of -0.31 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. Alpha Teknova's return on equity of -24.32% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-86.46%	-69.64%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Solid Biosciences presently has a consensus target price of $16.36, suggesting a potential upside of 114.46%. Alpha Teknova has a consensus target price of $8.00, suggesting a potential upside of 115.05%. Given Alpha Teknova's higher possible upside, analysts clearly believe Alpha Teknova is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Solid Biosciences has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Alpha Teknova has higher revenue and earnings than Solid Biosciences. Alpha Teknova is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A

Summary

Alpha Teknova beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Alpha Teknova compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CytomX Therapeutics had 15 more articles in the media than Alpha Teknova. MarketBeat recorded 20 mentions for CytomX Therapeutics and 5 mentions for Alpha Teknova. CytomX Therapeutics' average media sentiment score of 0.75 beat Alpha Teknova's score of 0.41 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Teknova has higher revenue and earnings than CytomX Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	18.10	-$17.37M	-$0.41	N/A
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A

CytomX Therapeutics currently has a consensus price target of $12.78, indicating a potential upside of 238.04%. Alpha Teknova has a consensus price target of $8.00, indicating a potential upside of 115.05%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CytomX Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Alpha Teknova has a net margin of -41.07% compared to CytomX Therapeutics' net margin of -166.40%. Alpha Teknova's return on equity of -24.32% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Summary

CytomX Therapeutics beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.

Get Alpha Teknova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TKNO vs. The Competition

Export

Metric	Alpha Teknova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$199.43M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-11.63	18.81	20.87	25.58
Price / Sales	4.92	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.07	6.74	9.86	6.70
Net Income	-$17.26M	$24.11M	$3.55B	$333.77M
7 Day Performance	-7.00%	0.07%	-0.32%	0.45%
1 Month Performance	22.77%	0.84%	1.34%	4.06%
1 Year Performance	-42.94%	78.10%	41.03%	36.21%

Alpha Teknova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TKNO Alpha Teknova	2.448 of 5 stars	$3.72 -4.9%	$8.00 +115.1%	-42.0%	$199.43M	$40.52M	N/A	240
IVA Inventiva	2.8068 of 5 stars	$5.42 +2.8%	$16.56 +205.5%	+54.7%	$769.16M	$5.07M	N/A	100	Positive News
GYRE Gyre Therapeutics	2.3281 of 5 stars	$7.78 -1.8%	$17.00 +118.5%	-36.7%	$768.19M	$116.59M	778.78	40	Analyst Downgrade Analyst Revision
BIOA BioAge Labs	3.0231 of 5 stars	$16.68 +0.4%	$46.25 +177.3%	N/A	$737.59M	$8.99M	N/A	N/A	Earnings Report Analyst Forecast
SLDB Solid Biosciences	2.9107 of 5 stars	$6.90 -4.6%	$16.09 +133.2%	+164.5%	$711.53M	N/A	N/A	100	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TKNO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpha Teknova (TKNO) Competitors

TKNO vs. IVA, GYRE, BIOA, SLDB, and CTMX

How does Alpha Teknova compare to Inventiva?

Summary

How does Alpha Teknova compare to Gyre Therapeutics?

Summary

How does Alpha Teknova compare to BioAge Labs?

Summary

How does Alpha Teknova compare to Solid Biosciences?

Summary

How does Alpha Teknova compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpha Teknova (TKNO) Competitors

TKNO vs. IVA, GYRE, BIOA, SLDB, and CTMX

How does Alpha Teknova compare to Inventiva?

Which has more volatility and risk, IVA or TKNO?

Which has higher valuation & earnings, IVA or TKNO?

Does the media refer more to IVA or TKNO?

Do institutionals & insiders believe in IVA or TKNO?

Is IVA or TKNO more profitable?

Do analysts recommend IVA or TKNO?

Summary

How does Alpha Teknova compare to Gyre Therapeutics?

Is TKNO or GYRE more profitable?

Which has more risk & volatility, TKNO or GYRE?

Do insiders & institutionals hold more shares of TKNO or GYRE?

Which has preferable earnings and valuation, TKNO or GYRE?

Does the media prefer TKNO or GYRE?

Do analysts recommend TKNO or GYRE?

Summary

How does Alpha Teknova compare to BioAge Labs?

Which has more volatility and risk, BIOA or TKNO?

Do insiders & institutionals hold more shares of BIOA or TKNO?

Do analysts recommend BIOA or TKNO?

Is BIOA or TKNO more profitable?

Which has better earnings & valuation, BIOA or TKNO?

Does the media prefer BIOA or TKNO?

Summary

How does Alpha Teknova compare to Solid Biosciences?

Do institutionals & insiders have more ownership in SLDB or TKNO?

Does the media favor SLDB or TKNO?

Is SLDB or TKNO more profitable?

Do analysts recommend SLDB or TKNO?

Which has more risk and volatility, SLDB or TKNO?

Which has stronger valuation and earnings, SLDB or TKNO?

Summary

How does Alpha Teknova compare to CytomX Therapeutics?

Do insiders & institutionals believe in CTMX or TKNO?

Does the media prefer CTMX or TKNO?

Which has better earnings & valuation, CTMX or TKNO?

Do analysts recommend CTMX or TKNO?

Which has more volatility & risk, CTMX or TKNO?

Is CTMX or TKNO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO vs. The Competition

Alpha Teknova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools